MTOR and acute myeloid leukemia: Thus, PI3K/mTOR inhibitors affect stromal cell cytokine release at the same concentrations that affect the release by the primary AML cells, and the drugs seem to have an overall proangiogenic effect on the chemokine release (maintained high CXCL8, decreased CXCL9-11); this effect is further supported by increased MMP-10 release by stromal cells.